module 4: screening
DESCRIPTION
Module 4: Screening. Developed through the APTR Initiative to Enhance Prevention and Population Health Education in collaboration with the Brody School of Medicine at East Carolina University with funding from the Centers for Disease Control and Prevention. Acknowledgments. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/1.jpg)
Module 4: Screening
Developed through the APTR Initiative to Enhance Prevention and Population Health Education in collaboration with the Brody School of Medicine at East Carolina University with funding from the Centers for Disease Control and Prevention
![Page 2: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/2.jpg)
Acknowledgments
APTR wishes to acknowledge the following individuals that developed this module:
Anna Zendell, PhD, MSWCenter for Public Health Continuing EducationUniversity at Albany School of Public Health
Joseph Nicholas, MD, MPHUniversity of Rochester School of Medicine
Mary Applegate, MD, MPHUniversity at Albany School of Public Health
Cheryl Reeves, MS, MLSCenter for Public Health Continuing EducationUniversity at Albany School of Public Health
This education module is made possible through the Centers for Disease Control and Prevention (CDC) and the Association for Prevention Teaching and Research (APTR) Cooperative Agreement, No. 5U50CD300860. The module represents the opinions of the author(s) and does not necessarily represent the views of the Centers for Disease Control and Prevention or the Association for Prevention Teaching and Research.
![Page 3: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/3.jpg)
Presentation Objectives
1. Define screening and identify appropriate conditions for screening
2. Evaluate screening tests in terms of their validity, results and generalizability
3. Evaluate the effectiveness of a screening program and discuss the common biases
4. Discuss ethical considerations in screening
![Page 4: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/4.jpg)
Introduction to Screening
![Page 5: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/5.jpg)
As you watch this clip and complete the module, think about the implications for patient screening based on this technology
Medical concerns?
Ethical considerations?
Access issues?
Informed decision-making after screening?
http://www.youtube.com/watch?v=6hlMlbmcSHg
Oprah’s Full Body Scan
![Page 6: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/6.jpg)
Preventive Medicine & Public Health
Share common goals Enhance quality of life of patients
▪ Health promotion▪ Disease and injury prevention
Preventive medicine promotes these goals at the individual and population levels, while public health focuses on populations.
![Page 7: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/7.jpg)
Primary Prevention
Secondary Prevention
Tertiary Prevention
Prevention – Brief Overview
McKenzie et al.: 2008
![Page 8: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/8.jpg)
Screening Defined
Presumptive identification of an unrecognized disease through tests, examinations, or other procedures which can be applied rapidly
Screening tests sort out apparently well persons who probably have a disease from those who probably do not.
![Page 9: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/9.jpg)
Early detection Leads to early treatment Can lead to a decrease in morbidity and mortality Can break the chain of transmission and development of
new cases Is often cost-effective
The human body is continually changing
Jekel et al:, 1996; McKenzie et al:, 2008; Londrigan & Lewenson: 2011
Importance of Screening
![Page 10: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/10.jpg)
Screening-Diagnosis Connection
Screening starts before diagnosis History questions Physical exam findings Lab tests Pre-test probability
Results of screening trigger diagnostic work-up and preventive interventions
Jekel et al:, 1996; McKenzie et al:, 2008
![Page 11: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/11.jpg)
Screening versus Diagnostic Tests
Diagnostic Test
Screening Test ≠
![Page 12: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/12.jpg)
Screening versus Diagnostic Tests
Diagnostic Test
Screening Test ≠Identifies asymptomatic people who may have a disease
![Page 13: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/13.jpg)
Screening versus Diagnostic Tests
Screening Test ≠Identifies asymptomatic people who may have a disease
Diagnostic Test
Determines presence or absence of disease when patient shows signs or symptoms
![Page 14: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/14.jpg)
Characteristics of a Good Screening Test
Simple Rapid Inexpensive Safe Available Acceptable
![Page 15: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/15.jpg)
Common Screening Tests
![Page 16: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/16.jpg)
Common Disease Screenings
Pap smear screens for ___________________________ Fasting blood sugar screens for _________________ Fecal occult blood test screens for ______________ Blood pressure screens for ______________________ Bone densitometry screens for _________________ PSA test screens for _____________________________ PPD test screens for _____________________________ Mammography screens for ______________________
USPSTF: 2009
![Page 17: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/17.jpg)
Common Disease Screenings
Pap smear screens for cervical cancer Fasting blood sugar screens for diabetes Fecal occult blood test screens for colorectal cancer Blood pressure screens for hypertension Bone densitometry screens for osteoporosis & osteopenia PSA test screens for prostate cancer PPD test screens for tuberculosis Mammography screens for breast cancer.
USPSTF: 2009
![Page 18: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/18.jpg)
Obesity Dental caries, oral cancer Drugs, Alcohol, and
Tobacco
Weight, Body Mass Index Oral examination Urine test, NMASSIST, or
Flagerstrom Tolerance Test for Nicotine Dependency
http://www.drugabuse.gov/NIDAMED/screening/
Common Wellness Screenings
![Page 19: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/19.jpg)
Standard practice Annual mammograms for women age 40+ years Start earlier if family history of breast cancer
2009 US Preventive Services Task Force (USPSTF) recommendations Mammograms not universal for women age 40-50 years Bi-annual mammograms for women 50+ years
Cost-benefit analysis False positives Unnecessary invasive procedures
Breast Cancer Screening
![Page 20: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/20.jpg)
Multiple screening options Colonoscopy – gold standard Sigmoidoscopy Virtual colonoscopy – CT colonoscopy Barium enema Fecal testing – occult blood, DNA test
Recommended age, frequency vary by test and family history
Colon Cancer Screening
![Page 21: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/21.jpg)
Case Study Colorectal Cancer Screening
Practice evaluation of diagnostic test characteristics and screening programs
Discuss prevention concepts
Apply this at patient and population level
![Page 22: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/22.jpg)
Mandatory universal screen for disorders, including metabolic, hormonal, hematologic, and infectious conditions
States vary in what diseases they test for Heel prick blood test 24-48 hours post birth - if done too
early, metabolic disease may not show up in blood Family history may indicate need for additional screens
Newborn Screening
![Page 23: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/23.jpg)
Evaluation of Screening Tests
![Page 24: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/24.jpg)
Reliability and validity are central concepts in evaluating tests
Distinction between reliability and validity Reliability: consistency of test at different times or under
differing conditions
Validity: how well test distinguishes between who has disease and who does not
Fortune & Reid: 1998; Jekel et al:, 1996
Evaluating Tests
![Page 25: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/25.jpg)
Characteristics of a Screening Test
VALIDITY and RELIABILITY
Fortune & Reid: 1998
![Page 26: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/26.jpg)
Also known as consistency Ability to yield the same results with repeated
measurements of same construct Degree to which results are free from random error
Jekel: 1996; Al-Eisa: 2009
Reliability
![Page 27: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/27.jpg)
Jekel: 1996; Al-Eisa: 2009
Intra-subject
Common Types of Reliability
![Page 28: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/28.jpg)
Intra-subject
Intra-rater
Common Types of Reliability
Jekel: 1996; Al-Eisa: 2009
![Page 29: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/29.jpg)
Intra-subject
Inter-rater
Intra-rater
Common Types of Reliability
Jekel: 1996; Al-Eisa: 2009
![Page 30: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/30.jpg)
Intra-subject
Instrument Inter-rater
Intra-rater
Common Types of Reliability
Jekel: 1996; Al-Eisa: 2009
![Page 31: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/31.jpg)
Measures validity of screening tests Ability to identify those with disease correctly
Minimizes false negatives – if test highly sensitive SNOUT – Sensitive test with Negative result rules
OUT disease
Sensitivity
![Page 32: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/32.jpg)
Ability to identify those without disease correctly Minimizes false positives – if test highly specific SPIN – Specific test with Positive result rules IN
disease
Specificity
![Page 33: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/33.jpg)
Relationship Between Sensitivity and Specificity
PSA level Sensitivity Specificity
1.0 100 21
2.0 100 48
3.0 100 60
4.0 99 73
5.0 96 76
6.0 94 79
7.0 90 83
8.0 90 88
9.0 68 90
10.0 54 93
11.0 47 94
12.0 30 95
13.0 23 96
14.0 17 97
15.0 11 97 Morgan TO et al; NEJM, 1996
![Page 34: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/34.jpg)
The 2x2 Table
True Positive
Disease Present Disease Absent
Test +
Test -
False Positive
False Negative
True Negative
![Page 35: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/35.jpg)
Sensitivity=
True positive False positive
False negative True negative
Present AbsentDISEASE
Test +
Test -
True positives
True positives + false negatives
Sensitivity
![Page 36: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/36.jpg)
Specificity
True positive False positive
False negative True negative
Present AbsentDISEASE
Test +
Test -
= SpecificityTrue negatives
True negatives + false positives
![Page 37: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/37.jpg)
Predictive Values
Positive predictive value Negative predictive value
![Page 38: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/38.jpg)
Positive Predictive Value (PPV)
NOT inherent characteristic of a screening test Percent of positive tests that are truly positive
If test result is positive, what is probability that the patient has the disease?
Is affected by several factors Specificity & specificity of the screening test Prevalence of disease
![Page 39: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/39.jpg)
Negative Predictive Value (NPV)
NOT inherent characteristic of a screening test Percent of negative tests that are truly negative
If test result is negative, what is the probability that patient does not have the disease?
![Page 40: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/40.jpg)
Sensitivity and specificity are constant for a particular test
PPV and NPV vary dramatically, depending on prevalence of target condition in population testedLow prevalence low PPV, high NPVHigh prevalence high PPV, low NPV
Test Characteristics and Population Tested
![Page 41: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/41.jpg)
0%
20%
40%
60%
80%
100%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
PVPPVN
Prevalence
Predictive Value and Prevalence(in test with 98% sensitivity, 92% specificity)
Pred
ictiv
e Va
lue
![Page 42: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/42.jpg)
Disease
Diseased Non-Diseased PVs↓
Test Result
Positive True Positive (TP) False Positive (FP) (Type 1 error)
TPTP + FP
Negative False Negative (FN)(Type II error) True Negative (TN) TN
TN +FN
SensitivityTP TP + FN
SpecificityTN
TN + FP
Predictive ValuesSample Calculations
![Page 43: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/43.jpg)
HIV Status
1,000 people at Prenatal Clinic HIV-Positive (15) HIV-Negative (985) 1.5% Prevalence
ELISA Result
Positive True Positive (14) False Positive (99)14
14 + 99= 12.4% PPV
Negative False Negative (1) True Negative (886)886
1 + 886= 99.9% NPV
Sensitivity (95%) Specificity (90%)
Positive Predictive ValueLow Prevalence
![Page 44: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/44.jpg)
HIV Status
1,000 people at STD Clinic HIV-Positive (60) HIV-Negative (940) 6% Prevalence
ELISA Result
Positive True Positive (57) False Positive (94)57
57 + 94= 37.75% PPV
Negative False Negative (3) True Negative (846)846
3 + 846= 99.6% NPV
Sensitivity (95%) Specificity (90%)
Positive Predictive ValueHigh Prevalence
![Page 45: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/45.jpg)
HIV Status
1,000 people at Clinic in Zambia HIV-Positive (240) HIV-Negative (760) 24% Prevalence
ELISA Result
Positive True Positive (228) False Positive (76)228
228 + 76= 75% PPV
Negative False Negative (12) True Negative (684)684
12 + 684= 98.3% NPV
Sensitivity (95%) Specificity (90%)
Positive Predictive ValueVery High Prevalence
![Page 46: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/46.jpg)
Multiple Screening TestsSimultaneous
Use of different tests concurrently to screen for same condition
Example: Prenatal multiple marker screening for Down Syndrome Measures levels of 3 biomarkers in mother’s blood:
▪ AFP: alpha-fetoprotein, protein produced by fetus
▪ hCG: human chorionic gonadotropin, hormone produced by placenta
▪ Estriol: a hormone produced by both fetus and placenta
Results of ALL 3 tests increases sensitivity and specificity
![Page 47: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/47.jpg)
Multiple Screening TestsSequential
Use of two-stage screening to target testing efforts Example: Early pregnancy gestational diabetes
screening First trimester risk assessment—identifies women at higher
risk of gestational diabetes Oral Glucose Tolerance Test (OGTT) right away for those
whose first screen indicates high risk
![Page 48: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/48.jpg)
Multiple Screening TestsSequential
Two-stage screening to maximize predictive value Example: HIV screening in suburban primary care
office Risk assessment questionnaire about sexual and drug use
history HIV blood test for all patients whose questionnaire
indicates risk factors for HIV infection
![Page 49: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/49.jpg)
Effectiveness of Screening Programs
![Page 50: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/50.jpg)
Test characteristics (sensitivity & specificity) alone are never sufficient for a sound decision about whether to use a screening test
Other screening considerations Benefits vs. risks Prevalence of target condition Inconvenience Costs/resource expenditures Patient values and cultural norms
Guyatt: 2009
Screening Effectiveness Evaluation
![Page 51: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/51.jpg)
Assessing a screening/diagnostic test Properties & accuracy Comparison of test to “gold standard”
Most definitive diagnostic procedure or best available laboratory test
Not always a gold standard for a procedure
USPSTF recommended
Study DesignTesting a Test
![Page 52: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/52.jpg)
![Page 53: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/53.jpg)
USPSTF Activities
Systematically reviews the evidence of effectiveness and develops recommendations for clinical preventive services
Recommendations include: Screening tests Counseling Preventive medications
Courtesy of Diana Pettiti, USPSTF: 2010
![Page 54: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/54.jpg)
USPSTF Methodology
1. Define analytic framework – outcomes & questions2. Define and retrieve relevant evidence 3. Evaluate QUALITY of studies (good, fair, poor)4. Synthesize and judge STRENGTH of overall
evidence (convincing, adequate, inadequate)5. Determine BALANCE of benefits and harms
Benefits – Harms = Net Benefit6. Link recommendation to judgment about net
benefits: Grades: A, B, C, D, I (inadequate evidence)
Courtesy of Diana Pettiti, USPSTF: 2010
![Page 55: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/55.jpg)
Critical Appraisal Questions
Do the studies have the appropriate research design to answer key questions?
Are the existing studies high quality?
Are the results of the studies applicable to the general US primary care population and setting?
Courtesy of Diana Pettiti, USPSTF: 2010
![Page 56: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/56.jpg)
Critical Appraisal Questions
How many relevant studies have been done?
How large are the studies?
How consistent are the results of the studies?
Are there other factors that help us assess the certainty of the evidence? (e.g. dose-response effects, biologic plausibility)
Courtesy of Diana Pettiti, USPSTF: 2010
![Page 57: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/57.jpg)
Certainty of Net Benefit Magnitude of Net Benefit
Substantial Moderate Small Zero/negative
High A B C D
Moderate B B C D
Low Insufficient (I Statement)
Courtesy of Diana Pettiti, USPSTF: 2010
Linking Recommendations to Benefits: USPSTF Recommendations
![Page 58: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/58.jpg)
Grade Grade Definition Suggestion for PracticeA USPSTF recommends the service.
There is high certainty that the net benefit is substantial. Offer or provide this service.
BThe USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.
Offer or provide this service.
CUSPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient.There is moderate or high certainty that the net benefit is small.
Offer or provide this service only if there are other considerations in support of the offering or providing the service in an individual patient.
DUSPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.
Discourage the use of this service.
IUSPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.
Read “Clinical Considerations” section of USPSTF Recommendation Statement. If offered the service, patients should understand the uncertainty about the balance of benefits and harms.
Courtesy of Diana Pettiti, USPSTF: 2010
Communicating USPSTF Recommendations
![Page 59: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/59.jpg)
Newer tests vs. gold standard Best tests for your population
Validity in your population Accessibility Cost Capacity of local health care system
Need a system in place to be able to screen AND to deal with positive results
Comparison of Screening Tools
![Page 60: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/60.jpg)
Liquid-basedPap smear –the NEW test
Patients withoutevidence of cervical cancer
NOCervical Cancer
NOCervical Cancer
Cervical Cancer
Cervical CancerStandardPap smear –the GOLD STANDARD
Testing a Test
![Page 61: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/61.jpg)
1. Are study methodology and results credible?
2. Have sensitivity, specificity and predictive values been calculated and reported?
3. Is the population tested similar to my patient population?
4. How can I use these results in a screening program or patient care?
5. Does this screening improve the present state of medical screening?
Evaluating Screening Research
![Page 62: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/62.jpg)
Lead time bias: over-estimation of survival rate among screening-detected cases
When survival is calculated from diagnosis point
Length bias: over-estimation of survival rate among screening-detected cases
Due to excess of slowly progressing cases among those identified by screening
Koretz: 2009
Screening Outcome ConsiderationsLong-term Outcomes
![Page 63: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/63.jpg)
To Screen or Not to ScreenEssential Criteria
Disease Test Treatment Cost ProgrammingCondition should be important health problem.
Test must be simple, safe, precise, valid.
Must be evidence of effective treatment and that early treatment will lead to better outcomes.
Evidence on cost- effectiveness of screening for interventions and outcomes.
Evidence from randomized controlled trials that program effective in reducing mortality and morbidity.
Epidemiology of disease must be understood.
Must be acceptable to population and health providers giving test.
Benefits outweigh physical and psychological harms if any.
Criteria/protocol on next steps for positive tests.
Protocols for implementation and evaluation of screening program.
![Page 64: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/64.jpg)
Pseudodisease
Definition: Identifying a disease that is unlikely to impact patient over lifetime Prostate or breast cancer may be present in body May never become clinically apparent
Identifying pseudodisease is nearly impossible until person dies from unrelated causes
Gold standard tests cannot predict future trajectory of a condition
Durgin: 2005
![Page 65: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/65.jpg)
Screening and Ethics
![Page 66: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/66.jpg)
Mandated screening Genetic testing Disparities Creation of screening program
Ethical Considerations
![Page 67: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/67.jpg)
Newborn screening Syphilis testing for marriage licenses TB screening for health care workers Drug testing for airline pilots
Mandatory Screening
![Page 68: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/68.jpg)
Need to assess costs vs. benefits at all levels Individual Societal Healthcare system
Mandatory Screening
![Page 69: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/69.jpg)
Pros Identify serious problems that could harm others OR where
immediate treatment is imperative Cons
Potential harm to patient autonomy Confidentiality concerns Testing low risk population reduces PPV Consequences of false positive tests
Mandatory Screening
![Page 70: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/70.jpg)
Learn if individual carries a gene for a disease and might pass it on to children
Screen unborn fetus for disease Test for genetic diseases in children or adults before
symptoms emerge
Genetics TestingBenefits
![Page 71: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/71.jpg)
Results difficult to interpret; not always clear cut Employment issues Health/life insurance consequences Added stress Costs Confidentiality Ownership of DNA
Genetic TestingConcerns
Kalb, 2006
![Page 72: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/72.jpg)
DisparitiesAccess to Screening
Geographic region Rural Inner city
Uninsured and underinsured Screening and follow-up testing/treatment Cost-prohibitive without health insurance
Minority and immigrant populations Lack of culturally competent healthcare providers Low health literacy
![Page 73: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/73.jpg)
Cross-cultural differences in health literacy and attitudes
Culturally relevant screening Screening practices may need to be adapted
DisparitiesCultural
![Page 74: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/74.jpg)
How ethical is it to: Use a test that may tell people they have condition
when they do not? Use a test that may tell people they do not have
condition when they actually do? Use a test if there is no system in place to treat those
who test positive?
Developing a Screening ProgramEthical Considerations
Truglio et al: 2011
![Page 75: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/75.jpg)
Strategic targeting for screening Groups with higher prevalence – increase PPV Provider vs. patient – who is more likely to request?
Growing body of evidence-based medicine allows us to: Identify more precise screening protocols Weigh benefits/drawbacks of screening test
Strategic screening can be cost-effective
Implications for Practice
![Page 76: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/76.jpg)
Summary
Screening is bedrock of secondary prevention Screening and diagnosis are not the same Sensitivity and specificity are characteristics of a
screening test that determine a test’s validity Predictive values are affected by sensitivity &
specificity of test and by prevalence of the disease Screening of high-risk populations increases positive
predictive value Screening decisions must weigh acceptability and
applicability to practitioner, population, and individual
![Page 77: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/77.jpg)
Collaborating Institutions
Department of Public HealthBrody School of Medicine at East Carolina University
Department of Community & Family MedicineDuke University School of Medicine
![Page 78: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/78.jpg)
Advisory Committee
Mike Barry, CAELorrie Basnight, MDNancy Bennett, MD, MSRuth Gaare Bernheim, JD, MPHAmber Berrian, MPHJames Cawley, MPH, PA-CJack Dillenberg, DDS, MPHKristine Gebbie, RN, DrPHAsim Jani, MD, MPH, FACP
Denise Koo, MD, MPHSuzanne Lazorick, MD, MPHRika Maeshiro, MD, MPHDan Mareck, MDSteve McCurdy, MD, MPHSusan M. Meyer, PhDSallie Rixey, MD, MEdNawraz Shawir, MBBS
![Page 79: Module 4: Screening](https://reader035.vdocument.in/reader035/viewer/2022062521/56816857550346895dde78fa/html5/thumbnails/79.jpg)
APTR
Sharon Hull, MD, MPHPresident
Allison L. LewisExecutive Director
O. Kent Nordvig, MEdProject Representative